Compare Moderna, Inc. (MRNA) vs Phillips 66 (PSX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs Phillips 66 — how do they compare? Moderna, Inc. trades at $61.82 (market cap $24.18B), while Phillips 66 trades at $225.65 (market cap $89.52B). The key difference: Phillips 66 is far larger — about 3.7× Moderna, Inc.'s market cap, and Phillips 66 pays a 2.26% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals.
| MRNA | PSX | |
|---|---|---|
Market Cap | $24.18B | $89.52B |
Sector | Health | Energy |
52-Week High | $81.80 | $224.36 |
52-Week Low | $22.36 | $120.04 |
Enterprise Value | $20.33B | $105.99B |
Dividend Yield | — | 2.26% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $59.81, up 1.08% today, with a bullish technical signal from moving averages and recent FDA approval for its mRNA flu vaccine mFLUSIVA. Despite beating Q2 2026 EPS estimates, revenue has declined from pandemic peaks, with a net income margin of -142.58% in 2026. The stock faces resistance near $61-$63, while support lies at $56-$59.
Outlook remains mixed; pipeline advancements in flu, Ebola, and oncology offer growth potential, but persistent losses and high valuation ratios pose risks. Analyst consensus is cautious with a $54.33 price target below current levels, reflecting concerns over profitability amid transitioning business focus.
Phillips 66 (PSX) trades at $215.52, up 5.69% in the last session, reflecting strong momentum. The stock exhibits bullish technical signals with key support at $208 and resistance at $219. Fundamentally, Q2 2026 EPS of $9.41 significantly beat estimates, driven by robust refining margins and high utilization rates. Recent news highlights the final investment decision for the $5 billion Western Gateway Pipeline joint venture, signaling growth in midstream operations.
Outlook remains positive with analyst consensus favoring Buy ratings (57%) and a $221.92 price target. Key opportunities include sustained refining strength and debt reduction, while risks involve volatile crude prices and geopolitical tensions affecting supply chains. Earnings growth and strategic projects underpin potential upside, but investors should monitor margin pressures and global energy dynamics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About Phillips 66
Phillips 66 is an independent refiner with 12 refineries that have a total crude throughput capacity of 2.0 million barrels per day, or mmb/d, after converting its 255 mb/d Alliance refinery to a terminal. The midstream segment comprises extensive transportation and NGL processing assets. It also includes its DCP Midstream joint venture, which holds 45 natural gas processing facilities, 11 NGL fractionation plants, and a natural gas pipeline system with 58,000 miles of pipeline. Its CPChem chemical joint venture operates facilities in the United States and the Middle East and primarily produces olefins and polyolefins.
Read more on PSX →
